Prevalence of Contact Allergy to Neomycin in Dermatitis Patients: A Systematic Review and Meta‐Analysis
Contact Dermatitis · 2025
DOI: 10.1111/cod.14784 ↗At a glance
Metaanalyse in Contact Dermatitis, 2025. Written by Mikkel Bak Jensen and 5 co-authors. Institution: National Allergy Research Centre, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen, Denmark. Major MEDLINE topics: Anti-Bacterial Agents, Dermatitis, Allergic Contact, Neomycin. Cited 8 times so far (Crossref); 88 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: The Danish Environmental Protection Agency under the Ministry of Environment of Denmark.
Abstract (original language)
Neomycin, an aminoglycoside antibiotic frequently employed in topical formulations, is a recognised allergen that is part of many baseline series and can cause contact allergy (CA) in both adults and children. It is an allergen of interest as it has a widespread use in over‐the‐counter and prescription products globally, but geographical variations may exist. This study aimed to establish prevalence estimates of CA to neomycin in dermatitis patients and to investigate potential geographical variations. Three databases (PubMed, Embase, and Web of Science) were screened, revealing 70 included studies comprising 456 372 adults and 17 720 children who underwent patch testing. The pooled prevalence of CA to neomycin was found to be 3.2% (95% confidence interval [CI]: 2.6%–3.8%) in adults and 4.3% (95% CI: 2.65%–6.3%) in children. The highest prevalences were observed in North America (adults: 6.4%; children: 8.1%) and South Asia (adults: 4.9%), while Europe showed lower rates (adults: 2.5%; children: 0.8%). Studies after the year 2000 indicated a prevalence of 2.1% in adults and 5.1% in children across geographical regions. These findings highlight a public health concern, particularly in regions with high prevalence rates. The study underscores the need for more restrictive use of neomycin to reduce the incidence of neomycin‐induced CA.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- National Allergy Research Centre, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen, Denmark.
- Institute of Clinical Medicine, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark.
- Department of Dermatology and Allergy, Herlev and Gentofte - Copenhagen University Hospital, Copenhagen, Denmark.
ORCID profiles: Mikkel Bak Jensen, Daniel Isufi, Christoffer Kursawe Larsen, Jakob Ferløv Baselius Schwensen, Farzad Alinaghi, Jeanne Duus Johansen
Funding
- The Danish Environmental Protection Agency under the Ministry of Environment of Denmark
Cite
APA
Jensen, M. B., Isufi, D., Larsen, C. K., Schwensen, J. F. B., Alinaghi, F., & Johansen, J. D. (2025). Prevalence of Contact Allergy to Neomycin in Dermatitis Patients: A Systematic Review and Meta‐Analysis. Contact Dermatitis. https://doi.org/10.1111/cod.14784
Vancouver
Jensen MB, Isufi D, Larsen CK, Schwensen JFB, Alinaghi F, Johansen JD. Prevalence of Contact Allergy to Neomycin in Dermatitis Patients: A Systematic Review and Meta‐Analysis. Contact Dermatitis. 2025. doi:10.1111/cod.14784
BibTeX
@article{Jensen2025,
author = {Jensen, Mikkel Bak and Isufi, Daniel and Larsen, Christoffer Kursawe and Schwensen, Jakob Ferløv Baselius and Alinaghi, Farzad and Johansen, Jeanne Duus},
title = {Prevalence of Contact Allergy to Neomycin in Dermatitis Patients: A Systematic Review and Meta‐Analysis},
journal = {Contact Dermatitis},
year = {2025},
doi = {10.1111/cod.14784}
}
EUVIMED